Home › Mutual Funds › Nippon India Mutual Fund › Nippon India Pharma Fund - Direct Plan - Growth Plan
Latest NAV & returns of NIPPON INDIA PRIVATE LTD.

Nippon India Pharma Fund - Direct Plan - Growth Plan

Add To Compare

previously known as Reliance Pharma Dir Gr until

625.013 (-0.219%)
NAV on July 24, 2026
Category Equity:
Sector - Healthcare
Investment StyleBox
Large Growth
Total Assets 9,044 cr
Turnover Ratio 14.27%
Expense Ratio 0.79%
Exit Load 1.00%if redeemed within
1 Months0.00%if redeemed after 1 Months
Returns
  • 1M: 0.84%
  • 1Y: 6.23%
  • 3M: 9.91%
  • 3Y: 19.94%
  • 6M: 14.91%
  • 5Y: 13.16%
Min Investment 5,000
Buy Now Start SIP
ADDITIONAL INFO
Fund Manager Sailesh Raj Bhan (Since over 21 years) Kinjal Desai (Since about 8 years) Amber Singhania (Since 5 months)
ISIN INF204K01I50
Fund Family Nippon India
P/E Ratio 38.20
P/B Ratio 5.65
Launch Date January 01, 2013
Benchmark BSE Healthcare TR INR
ASSET ALLOCATION
EQUITY DISTRIBUTION
RISK MEASURES (3 yrs)
vs BSE Healthcare TR INR

Alpha -0.78
Beta 0.89
R-Squared 94.72
Info Ratio -0.76
Tracking Err 3.95
Sortino 1.659
Sharpe 0.968
Std Dev 15.232
Risk -
SECTOR WEIGHTINGS (%)
Financial 0.0%
Industrial 0.0%
Technology 0.0%
Basic Materials 0.0%
Consumer Cyclical 0.0%
Utilities Services 0.0%
Healthcare Services 100.00%
Energy Services 0.00%
Communication Services 0.00%
Consumer Defensive 0.00%
Real Estate 0.00%
INVESTMENT OBJECTIVE

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

You will not receive any dividends. Your investments will get the largest benefit of compounding.

View Factsheet
-


Other plans of Nippon India Pharma


Other Equity funds by Nippon India

Data Partner
Click here to visit AMC website and
read all scheme related documents Nippon India Fund